Emmanuel Antonarakis, MD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    z-Alpha
    Date added:
    Date updated:
    11/09/2023
    Relationship end date:
    02/03/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Propella Therapeutics
    Date added:
    Date updated:
    11/09/2023
    Relationship end date:
    08/04/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Pfizer
    Date added:
    Date updated:
    11/09/2023
    Relationship end date:
    02/01/2022
  • Attribution:
    Self
    Type of financial relationship:
    Scientific Study or Trial (Oncology)
    Ineligible company:
    Orion
    Date added:
    Date updated:
    11/09/2023
  • Attribution:
    Self
    Type of financial relationship:
    Scientific Study or Trial (Oncology)
    Ineligible company:
    Merck
    Date added:
    Date updated:
    11/09/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Menarini Silicon Biosystems
    Date added:
    Date updated:
    11/09/2023
    Relationship end date:
    11/30/2022
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Hookipa Pharma
    Date added:
    Date updated:
    11/09/2023
    Relationship end date:
    10/14/2022
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Foundation Medicine
    Date added:
    Date updated:
    11/09/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Corcept Therapeutics
    Date added:
    Date updated:
    11/09/2023
    Relationship end date:
    03/01/2022
  • Attribution:
    Self
    Type of financial relationship:
    Scientific Study or Trial (Oncology)
    Ineligible company:
    Constellation Pharma
    Date added:
    Date updated:
    11/09/2023
    Relationship end date:
    05/01/2023

Pages

Return to PARPi: Precision Medicine in Advanced Prostate Cancer (2023)